Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

							, .				1								
1. Name and Address of Reporting Person* <u>Rich Cadmus</u>					2. Issuer Name and Ticker or Trading Symbol Aura Biosciences, Inc. [AURA]									eck all applic Directo	ector		10% Ov	wner	
(Last) (First) (Middle) C/O AURA BIOSCIENCES, INC. 80 GUEST STREET					3. Date of Earliest Transaction (Month/Day/Year) 01/19/2023								- 2		Officer (give title below) See Remarks Other (solution)			specify	
(Street) BOSTON	N M	A	01235 (Zip)		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line) <mark>〈</mark> Form f	Joint/Group Filing (Check Applicable filed by One Reporting Person filed by More than One Reporting in					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				action	ction 2A. Deemed Execution D		ed Date,	3. Transa Code (l	ction	4. Securities Acquired Disposed Of (D) (Instr. 5)		ired (A	A) or	5. Amou Securitie Benefici Owned F Reported	es ally following d	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	٧	Amount	t (A) or (D)		Price	Transact (Instr. 3				
Common Stock 01/19				0/2023			A		34,125	34,125 ⁽¹⁾ A		\$0.00	58	58,703		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Date,	Code (In			ive ies ed ed nstr.	5. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ve es ially ng d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisab		Expiration Date	Title	or Ni of	umber					
Stock Option (Right to Buy)	\$10.18	01/19/2023			A		52,500		(2)	(01/18/2033	Commo Stock	n 52	2,500	(2)	52,500)	D	

Explanation of Responses:

- 1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on the one year anniversary of the date of grant.
- 2. The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of January 19, 2023 with the remainder vesting thereafter pro-rata in 36 monthly installments.

Remarks:

Chief Medical Officer, Head of R&D

/s/ Julie Feder, as Attorney-in-

01/23/2023

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.